U.S. Patent No. 9,205,100, issued on December 8, 2015, relates to a novel method for treatment of lung disease or lung injury which is associated with lung transplantation. The patented method uses a proprietary combination of nucleic-acid inhibitors targeting two types of toll-like receptors, namely TLR2 and TLR4. Quark demonstrated that this novel inhibitor combination is capable of improving various symptoms associated with lung transplantation, including reduction of lung edema, restoration of lung pulmonary function and reduction of lung graft rejection.

Read moreā€¦